DOCSLIB.ORG

Protocol Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protocol Template SJCRH NCT00703820 (AML08) Initial version, dated: 04/03/2008, Submitted to CPSRMC 04/07/08. Resubmitted: 4/25/08 and 5/13/2008. Resubmitted to IRB 5/28/2008 and June 12, 2008. (IRB Approved: June 14, 2008) Activation Date: August 1, 2008 Amendment 1.0, dated: August 28, 2008 (IRB Approved: September 23, 2008) Amendment 2.0, dated: December 24, 2008 (IRB Approved: February 13, 2009) Amendment 3.0, dated: June 26, 2009 (IRB Approved: August 11, 2009). Activated: August 17, 2009 Amendment 4.0, dated: January 21, 2010 (IRB approved: March 11, 2010). Activated: March 19, 2010 Revision 4.1, dated April 13, 2010 (IRB approved: April 27, 2010). Activated: May 12, 2010 Revision 4.2, dated May 17, 2010 (IRB approved: June 1, 2010). Activated: June 7, 2010 Letter of Amendment #1: Deletion of Mylotarg, dated June 22, 2010 (IRB Approved: June 23, 2010). Activated: July 12, 2010 Amendment 5.0, dated July 8, 2010 (IRB Approved: August 26, 2010). Activated: August 31, 2010 Amendment 6.0, dated April 05, 2011(IRB Approved: May 26, 2011). Activated: June 8, 2011 Amendment 7.0, dated August 22, 2011(IRB Approved: October 3, 2011). Revision 7.1, dated October 05, 2011 (IRB Approved: October 24, 2011) Revision 7.2, dated February 01, 2012 (IRB Approved: February 8, 2012). Activated: March 1, 2012 Amendment 8.0, dated October 1, 2012 (IRB Approved: January 18, 2013) Activated: M arch 6, 2013 Revision 8.1, dated March 15, 2013 (IRB approved March 21, 2013) Activated: March 27, 2013 Amendment 9.0, dated June 13, 2013. Resubmitted to IRB July 12, 2013 (IRB approved: July 15, 2013). Revision 9.1, dated July 18, 2013. (IRB approved: July 19, 2013) Activated: August 28, 2013 Amendment 10.0: February 10, 2014. (IRB approved: February 12, 2014) Activated: February 18, 2014 Letter of Amendment #4, dated May 29, 2015 (IRB approved: May 29, 2015) Activated: June 1, 2015 Revision 10.1: June 2, 2016. (IRB approved: June 7, 2016) Activated: July 5, 2016 AML08: A PHASE III RANDOMIZED TRIAL OF CLOFARABINE PLUS CYTARABINE VERSUS CONVENTIONAL INDUCTION THERAPY AND A PHASE II STUDY OF NATURAL KILLER CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Principal Investigator Jeffrey E. Rubnitz, MD, PhD1 Other St. Jude Investigators James Downing, MD3 Stanley Pounds, PhD4 Aditya Gaur, MD, MBBS5 Ching-Hon Pui, MD1 Randall Hayden, MD3 Susana Raimondi, PhD3 Hiroto Inaba, MD, PhD1 Raul Ribeiro, MD1 John Choi, MD, PhD3 Brandon Triplett, MD2 Sima Jeha, MD1 St. Jude Children's Research Hospital 262 Danny Thomas Place Memphis, Tennessee 38105-2794 Telephone: (901) 595-3300 Additional contact information for St. Jude Principal Investigator: Office: 901-595-2388, Page operator: 901-595-3300 Pager: 901-595-3578, #0713, Cell phone: 901-216-1878 FAX: 901-521-9005, Email: [email protected] Departments of 1Oncology, 2Bone marrow Transplant & Cellular Therapy, 3Pathology, 4Biostatistics, 5Infectious Diseases Contents of this document may not be extracted without permission from the Principal Investigator. Revision 10.1, dated: 06-02-2016 IRB Approval date: 06-07-2016 Protocol document date: 06-02-2016 External Co-Investigators (Collaborating Institutions): Stanford University Medical Center Children’s Hospital of Michigan Pediatric Hematology/Oncology 3901 Beaubien Blvd. Packard Children’s Hospital Detroit, MI 48201 725 Welch Road Jeffrey Taub, MD Palo Alto, CA 94304 Gary Dahl, MD Dana-Farber Cancer Institute and Norman Lacayo, MD Children’s Hospital, Boston Pediatric Oncology Cook Children’s Medical Center 44 Binney Street Hematology/Oncology Boston, MA 02115 901 Seventh Avenue Barbara Degar, MD Suite 220 Fort Worth, TX 76104 Paul Bowman, MD Ken Heym, M.D. University of Chicago National University Health System, Pediatric Hematology/Oncology MC4060 Singapore University of Chicago Paediatric Hematology/Oncology/BMT 5841 S. Maryland Avenue University Children's Medical Institute Chicago, IL 60637 5 Lower Kent Ridge Road Singapore 119074 John Cunningham, M.D. Republic of Singapore Rady Children’s Hospital San Diego Allen Eng-Juh Yeoh, M.D. 3020 Children’s Way San Diego, CA 92123 Deborah E. Schiff, M.D. External Scientific Collaborators National University of Singapore Dario Campana, MD, PhD Elaine Coustan-Smith, MSc Revision 10.1, dated: 06-02-2016 IRB Approval date: 06-07-2016 Protocol document date: 06-02-2016 AML08: A PHASE III RANDOMIZED TRIAL OF CLOFARABINE PLUS CYTARABINE VERSUS CONVENTIONAL INDUCTION THERAPY AND A PHASE II STUDY OF NATURAL KILLER CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Letter of Amendment January 9, 2014 This letter is being sent as clarification that collaborating sites may choose to not participate in the vorinostat exploratory objective of this study, as proposed with amendment 9.0. If the decision is made that a site will opt out, then all applicable patients at that site will receive standard therapy for Induction II with LD-ADE alone. Since this objective is exploratory and does not require a specific number of patients, this will not adversely affect the study analyses. This information will be forthcoming with the next protocol amendment; however, sites may choose to opt out at any time. Revision 10.1, dated: 06-02-2016 IRB Approval date: 06-07-2016 Protocol document date: 06-02-2016 AML08: A PHASE III RANDOMIZED TRIAL OF CLOFARABINE PLUS CYTARABINE VERSUS CONVENTIONAL INDUCTION THERAPY AND A PHASE II STUDY OF NATURAL KILLER CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Letter of Amendment November 20, 2013 Rationale This letter is being sent as clarification that if Erwinia asparaginase is given (see Section 4.5 of protocol), it may be administered according to local institutional guidelines, either IV or IM. Currently, the protocol and consent state IV administration. These will be revised to IV or IM with the next protocol amendment. Collaborating sites may follow local administration guidelines for the administration of this commercially available agent. The following St. Jude guidelines may be used, but are not required: Administration For IV administration, Erwinia asparaginase will be diluted in 50 mL NS to infuse over 30 minutes to 1 hour via syringe. Erwinia asparaginase should be administered to run concurrently with IVF. (NS at TKO is sufficient.) Erwinia asparaginase should be administered at least 2 hours after an LP/IT since some cases of over sedation were reported when given “simultaneously” with sedation and/or an LP/IT at other institutions. Further, it is desirable to avoid asparaginase directly before an IT because asparaginase could possibly interfere with the efficacy of methotrexate. Erwinia asparaginase may also be administered IM. Monitoring and concerns for anaphylaxis Obtain vital signs pre infusion, and then remain at the patient’s bedside for the first 5 minutes. Visually observe the patient at 10 minutes, and directly observe and obtain vital signs at 15 minutes and at the end of the infusion. Repeat vital signs at discharge. Patients must remain in Revision 10.1, dated: 06-02-2016 IRB Approval date: 06-07-2016 Protocol document date: 06-02-2016 the Medicine Room for 1 hour after administration to be observed for adverse effects. Keep NS at TKO during the 1 hour post watch time unless otherwise ordered. To prepare for anaphylaxis: Have oxygen, suction and pulse oximetry at bedside during and after infusion Have readily available* the following medications: o Diphenhydramine 1 mg/kg (max 50 mg) for IV administration o Epinephrine (1:1000) 0.01 mL/kg (max 0.3 mL) for SQ administration o Hydrocortisone 100 mg/m2 for IV administration o NS for IV administration *Readily available means in the general area – such as the emergency medication box in the medicine room or inpatient areas. Revision 10.1, dated: 06-02-2016 IRB Approval date: 06-07-2016 Protocol document date: 06-02-2016 Revision 10.1, dated: 06-02-2016 IRB Approval date: 06-07-2016 Protocol document date: 06-02-2016 Table of Contents 1.0 OBJECTIVES ......................................................................................................... 1 1.1 Primary objective ................................................................................................ 1 1.2 Secondary objective ............................................................................................ 1 2.0 BACKGROUND AND RATIONALE ................................................................... 2 2.1 Background and rationale for therapy................................................................. 2 2.2 Background and rationale for correlative and biologic studies ........................ 20 3.0 ELIGIBILITY CRITERIA AND STUDY ENROLLMENT ............................... 27 3.1 Diagnostic criteria ............................................................................................. 27 3.2 Inclusion criteria – all participants .................................................................... 28 3.3 Exclusion criteria – all participants................................................................... 28 3.4 Criteria for randomization................................................................................. 28 3.5 Enrollment on study .......................................................................................... 29 4.0 TREATMENT PLAN ........................................................................................... 29 4.1 General overview .............................................................................................
Load more

Recommended publications
  • A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
    NCT# 01596699 A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Protocol Number: CC #110819 Version Number: 7.0 Version Date: June 6, 2013 Study Drug: Clofarabine Principal Investigator (Sponsor-Investigator) Christopher C. Dvorak, MD Co-Investigators Janel Long-Boyle, PharmD, PhD Morton Cowan, MD Biljana Horn, MD James Huang, MD Robert Goldsby, MD Kristin Ammon, MD Justin Wahlstrom, MD Statistician Stephen Shiboski, PhD Clinical Research Coordinator Revision History Version #1.0 9/19/11 Version #2.0 11/8/11 Version #3.1 02/23/12 Version #4.0 04/10/12 Version #5.0 04/30/12 Version #6.0 08/09/12 Version #7.0 06/07/13 Clofarabine Version 4.0, 04/10/12 Page 1 of 33 1.0 Hypothesis and Specific Aims: 1.1 Hypothesis: The addition of Clofarabine to standard Busulfan and Fludarabine prior to allogeneic hematopoietic cell transplant (HCT) will be safe and will improve engraftment rates of children with non-malignant diseases or decrease relapse rates of patients with high-risk myeloid malignancies. 1.2 Specific Aims: 1.2.1 Primary Objective: To determine the toxicity of the addition of Clofarabine to a conditioning backbone of Busulfan plus Fludarabine in patients with myeloid malignancies and non-malignant diseases undergoing allogeneic HCT. 1.2.2 Secondary Objectives: a. To determine if the addition of Clofarabine to a conditioning backbone of Busulfan plus Fludarabine improves the engraftment rate of patients with non-malignant diseases (Stratum A) undergoing allogeneic HCT as compared to historic controls.
    [Show full text]
  • 214120Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 214120Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA Multidisciplinary Review and Evaluation Application Number NDA 214120 Application Type Type 3 Priority or Standard Priority Submit Date 3/3/2020 Received Date 3/3/2020 PDUFA Goal Date 9/3/2020 Office/Division OOD/DHM1 Review Completion Date 9/1/2020 Applicant Celgene Corporation Established Name Azacitidine (Proposed) Trade Name Onureg Pharmacologic Class Nucleoside metabolic inhibitor Formulations Tablet (200 mg, 300 mg) (b) (4) Applicant Proposed Indication/Population Recommendation on Regulatory Regular approval Action Recommended Indication/ For continued treatment of adult patients with acute Population myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. SNOMED CT for the Recommended 91861009 Indication/Population Recommended Dosing Regimen 300 mg orally daily on Days 1 through 14 of each 28-day cycle Reference ID: 4664570 NDA Multidisciplinary Review and Evaluation NDA 214120 Onureg (azacitidine tablets) TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................................... 2 TABLE OF TABLES .......................................................................................................................................
    [Show full text]
  • Clofarabine/Busulfan-Based Reduced Intensity
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 93), pp: 36603-36612 Research Paper Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC Amandine Le Bourgeois1, Myriam Labopin2, Mathieu Leclerc3, Régis Peffault de Latour4, Jean-Henri Bourhis5, Patrice Ceballos6, Corentin Orvain7, Hélène Labussière Wallet8, Karin Bilger9, Didier Blaise10, Marie-Thérese Rubio11, Thierry Guillaume1, Mohamad Mohty2, Patrice Chevallier1 and on behalf of Société Francophone de Greffe de Moelle et de Thérapie Cellulaire 1Department of Hematology, CHU Hôtel Dieu, Nantes, France 2Department of Hematology, Hôpital Saint Antoine, Paris, France 3Department of Hematology, Hôpital Henri Mondor, Créteil, France 4Department of Hematology, Hôpital Saint Louis, Université Paris 7, Denis Diderot, Paris, France 5Department of Hematology, Hôpital Gustave Roussy, Paris, France 6Department of Hematology, CHU de Montpellier, Montpellier, France 7Department of Hematology, CHU d’Angers, Angers, France 8Department of Hematology, Centre Hospitalier Lyon Sud, Lyon, France 9Department of Hematology, CHU Strasbourg, Strasbourg, France 10Department of Hematology, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France 11Department of Hematology, CHU Nancy, Nancy, France Correspondence to: Amandine Le Bourgeois, email: [email protected] Patrice Chevallier, email: [email protected] Keywords: allogeneic stem cell transplantation; clofarabine; busulfan; reduced intensity conditioning regimen; acute myeloid leukemia Received: August 24, 2018 Accepted: November 01, 2018 Published: November 27, 2018 Copyright: Bourgeois et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • Clofarabine (Clolar®) (“Kloe-FAR-A-Been”)
    Clofarabine (Clolar®) (“kloe-FAR-a-been”) How drug is given: by vein (IV) Purpose: To treat leukemia. Things that may occur during or within hours of each treatment • Changes in your pulse and blood pressure may occur. • You may have nausea, vomiting, and/or loss of appetite. Nausea and vomiting may begin soon after the drug is given and may last more than 24 hours. You may be given medicine to help with this. • It is important to drink extra fluids after receiving this medication. Things that may occur a few days to weeks later 1. If you start to feel joint pain, swelling, weakness or stiffness, call your cancer care team. 2. Loose stools or diarrhea may occur within a few days after the drug is started. You may take loperamide (Imodium A-D®) to help control diarrhea. You can buy this at most drug stores. Be sure to also drink more fluids (water, juice, sports drinks). If these do not help within 24 hours, call your cancer care team. 3. Some patients may feel very tired, also known as fatigue. You may need to rest or take naps more often. Mild to moderate exercise can also be helpful in maintaining your energy. 4. Your blood cell counts may drop. This is known as bone marrow suppression. This includes a decrease in your: • Red blood cells, which carry oxygen in your body to help give you energy • White blood cells, which fight infection in your body • Platelets, which help clot the blood to stop bleeding This may happen 7 to 14 days after the drug is given and then blood counts should return to normal.
    [Show full text]
  • Mitomycin C: Indications for Use and Safe Practice in Ophthalmology Published by American Society of Ophthalmic Registered Nurses
    Mitomycin C: Indications for Use and Safe Practice in Ophthalmology Published by American Society of Ophthalmic Registered Nurses Editor Susan Clouser, RN, MSN, CRNO American Society of Ophthalmic Registered Nurses 655 Beach Street, San Francisco, CA 94109 1 This publication includes independent authors’ guidelines for the safe use and handling of mitomycin C in ophthalmic practices. Readers should use these guidelines as a resource only. These guidelines should never take precedence over manufacturers’ recommended practices, facilities policies and procedures, or compliance with federal regulations. Information in this publication may assist facilities in developing policies and procedures specifc to their needs and practice environment. American Society of Ophthalmic Registered Nurses For questions regarding content or association issues contact ASORN at [email protected] or 1.415.561.8513. Copyright © 2011 by American Society of Ophthalmic Registered Nurses American Society of Ophthalmic Registered Nurses has the exclusive rights to reproduce this work, to prepare derivative works from this work, to publicly distribute this work, to publicly perform this work and to publicly display this work. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of American Society of Ophthalmic Registered Nurses. Printed in the United States of America 10 9 8 7 6 5 4 3 2 1 ACKNOWLEDGMENTS The development of this educational resource would not have been possible without the knowledge and expertise of the ophthalmologists and ophthalmic registered nurses who wrote the content and the subsequent reviewers who provided valuable input.
    [Show full text]
  • Salvage Chemotherapy Regimens for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Are Associated with Complete Response Rates of 30 - 60%
    Abstract Background: Salvage chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia (AML) are associated with complete response rates of 30 - 60%. Determining the superiority of one treatment over another is difficult due to the lack of comparative data. Clofarabine and cladribine based regimens appear to be superior to combinations of mitoxantrone, etoposide, and cytarabine (MEC). However, there are no data comparing treatments with these purine analogs to each other. Therefore, we conducted a retrospective study of GCLAC (clofarabine 25 mg/m2 IV days 1-5, cytarabine 2 gm/m2 IV days 1-5, and G-CSF) and CLAG (cladribine 5 mg/m2 IV days 1-5, cytarabine 2 gm/m2 IV days 1-5, and G-CSF). Methods: We identified 41 consecutive patients with pathologically diagnosed relapsed or refractory AML who received either GCLAC or CLAG between 2011 and 2014. The primary outcome was the complete response rate (CRi or CR) as defined by the International Working Group. Secondary outcomes included the percentage of patients who underwent allogenic stem cell transplant, relapse free survival (RFS), and overall survival (OS). Fisher’s exact and Wilcoxon Rank Sum tests were used to compare patient characteristics and response rates. The Kaplan Meier method and Log Rank tests were used to evaluate RFS and OS. Results: We found no significant differences in the baseline characteristics of patients treated with GCLAC (n=22) or CLAG (n=19) including age, race, gender, organ function, or cytogenetic risk group (table 1). There were also no significant differences in the percentage of relapsed patients (36% vs.
    [Show full text]
  • Evoltra, INN-Clofarabine
    1 SCIENTIFIC DISCUSSION 1.1 Problem statement Acute leukemia is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies. The two most common types of acute leukemia in children are acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). ALL is characterised by malignant transformation of lymphoid progenitor cells and is the most common of the paediatric leukaemias. It occurs about 5 times more commonly than does AML. In the UK, it has been estimated that around 450 new cases of leukemia are diagnosed each year. Over the years, a large number of antineoplastic agents have been evaluated in standardized research protocols. Survival rates for ALL and AML have improved dramatically during the past 20 years, due to the development of new combination regimens. However, approximately 20-25% of ALL in remission still relapse. Children with ALL at high risk of relapse are those with T-cell phenotype, older than 10 years or younger than 1 year of age, with white blood cell count (WBC) larger than 50,000/µl, and with unfavourable cytogenetics (like the Philadelphia chromosome). In spite of efforts to develop new therapeutic agents and novel treatments for relapsed leukemia, there are still limited therapeutic options for these patients and their prognosis is very poor. In some cases, remission induction is attempted with an intensive chemotherapy and/or a stem cell transplantation. In general, given the intensity and number of previous chemotherapeutic regimens, patients with ALL in relapse have a broad resistance to many currently used agents and have concurrent conditions and accumulated organ toxicity, making it difficult to induce a second or third complete remission.
    [Show full text]
  • Northwest Medical Benefit Formulary (List of Covered Drugs) Please Read
    Northwest Medical Benefit Formulary (List of Covered Drugs) Please Read: This document contains information about the drugs we cover when they are administered to you in a Participating Medical Office. What is the Kaiser Permanente Northwest Medical Benefit Formulary? A formulary is a list of covered drugs chosen by a group of Kaiser Permanente physicians and pharmacists known as the Formulary and Therapeutics Committee. This committee meets regularly to evaluate and select the safest, most effective medications for our members. Kaiser Permanente Formulary The formulary list that begins on the next page provides information about some of the drugs covered by our plan when they are administered to you in a Participating Medical Office. Depending on your medical benefits, you may pay a cost share for the drug itself. The first column of the chart lists the drug’s generic name. The second column lists the brand name. Most administered medications and vaccines are only available as brand name drugs. Contraceptive Drugs and Devices Your provider may prescribe as medically necessary any FDA-approved contraceptive drug or device, including those on this formulary, which you will receive at no cost share. Last Updated 09/01/2021 Generic Name Brand Name Clinic Administered Medications (ADMD) ABATACEPT ORENCIA ABOBOTULINUM TOXIN A DYSPORT ADALIMUMAB HUMIRA ADO-TRASTUZUMAB EMTANSINE KADCYLA AFAMELANOTIDE ACETATE SCENESSE AFLIBERCEPT EYLEA AGALSIDASE BETA FABRAZYME ALDESLEUKIN PROLEUKIN ALEMTUZUMAB LEMTRADA ALGLUCOSIDASE ALFA LUMIZYME ARALAST, GLASSIA,
    [Show full text]
  • Comparison of Clofarabine-Based Regimens Versus Etoposide Plus
    Archives of Hematology and Blood Diseases ISSN: 2639-3581 Volume 3, Issue 1, 2020, PP: 01-08 Comparison of Clofarabine-Based Regimens Versus Etoposide Plus Mitoxantrone as Salvage Chemotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia Robert Walchack1*, Zelia Bowman2, Sijin Wen3, Nilay Shah4, Kelly G. Ross4, Abraham S. Kanate4, Aaron Cumpston1,4 1Department of Pharmacy, West Virginia University Medicine, Morgantown, WV, USA. 2Section of Hematology/Oncology, West Virginia University, Morgantown, WV, USA. 3Department of Biostatistics, West Virginia University, Morgantown, WV, USA. 4Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, WV, USA. [email protected] *Corresponding Author: Robert Walchack, PharmD, BCOP, West Virginia University Medicine 1 Medical Center Drive Morgantown, WV 26506, USA. Abstract Introduction: There is insufficient evidence regarding the optimal chemotherapy regimen for treatment of relapsed or refractory acute myeloid leukemia (RR-AML). We retrospectively compared the outcomes and toxicities between salvage chemotherapy with etoposide plus mitoxantrone (EM) versus clofarabine-based regimens in patients with RR-AML. Materials and Methods: Consecutive patients with RR-AML who received > 1 cycle of EM or a clofarabine- based regimen between March 2003 and April 2017. Results: A total of 93 patients were included in the study. Sixty-nine patients received EM and 24 patients received clofarabine-based regimens. Baseline characteristics were matched, except for a higher rate of previous EM therapy and primary refractory disease in the clofarabine arm. The overall remission rate (complete remission plus complete remission with incomplete hematologic recovery) was 36.2% in the EM arm versus 29.2% in the clofarabine arm (p = 0.62).
    [Show full text]
  • Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients with Breast Cancer: Estimates from SEER-Medicare Data
    Supplemental online content for: Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data Anne A. Eaton, MS; Camelia S. Sima, MD, MS; and Katherine S. Panageas, DrPH J Natl Compr Canc Netw 2016;14(1):57–65 • eAppendix 1: J-Codes Representing Intravenous Chemotherapy • eAppendix 2: Established Sequential Adjuvant Chemotherapy Regimens for Breast Cancer • eTable 1: Patient Characteristics © JNCCN—Journal of the National Comprehensive Cancer Network | Volume 14 Number 1 | January 2016 Eaton et al - 1 eAppendix 1: J-Codes Representing Intravenous Chemotherapy J-Code Agent J-Code Agent J9000 Injection, doxorubicin HCl, 10 mg J9165 Injection, diethylstilbestrol diphosphate, 250 J9001 Injection, doxorubicin HCl, all lipid mg formulations, 10 mg J9170 Injection, docetaxel, 20 mg J9010 Injection, alemtuzumab, 10 mg J9171 Injection, docetaxel, 1 mg J9015 Injection, aldesleukin, per single use vial J9175 Injection, Elliotts’ B solution, 1 ml J9017 Injection, arsenic trioxide, 1 mg J9178 Injection, epirubicin HCl, 2 mg J9020 Injection, asparaginase, 10,000 units J9179 Injection, eribulin mesylate, 0.1 mg J9025 Injection, azacitidine, 1 mg J9180 Epirubicin HCl, 50 mg J9027 Injection, clofarabine, 1 mg J9181 Injection, etoposide, 10 mg J9031 BCG (intravesical) per instillation J9182 Etoposide, 100 mg J9033 Injection, bendamustine HCl, 1 mg J9185 Injection, fludarabine phosphate, 50 mg J9035 Injection, bevacizumab, 10 mg J9190 Injection, fluorouracil, 500 mg J9040 Injection,
    [Show full text]
  • Clofarabine Experience in Children with Multi-Relapsed Acute Leukemia Çoklu Relaps Yapan Akut Lösemili Çocuklarda Klofarabin Tecrübemiz
    Letter to the Editor DOI: 10.4274/tjh.2013.0297 Clofarabine Experience in Children with Multi-Relapsed Acute Leukemia Çoklu Relaps Yapan Akut Lösemili Çocuklarda Klofarabin Tecrübemiz Zeynep Karakaş, Begüm Şirin Koç, Serap Karaman, Sema Anak, Ayşegül Ünüvar, Ezgi Uysalol, Ömer Devecioğlu, Leyla Ağaoğlu, Gülyüz Öztürk İstanbul University İstanbul Faculty of Medicine, Department of Pediatric Hematology, Division Oncology, İstanbul, Turkey To the Editor, stem cell transplantation (HSCT) (Table 1). Of these 3 Although clofarabine is known as an effective novel agent patients who had allogeneic HSCT after remission with the in relapsed acute leukemia [1,2,3,4,5], determining the CLOVE protocol, all of them relapsed after the HSCT. One of optimum combination with other agents and the optimum them received a second allogeneic HSCT after the remission time to use remains a challenge. Clofarabine is recommended with the second therapy protocol with clofarabine; she to be used after 2 protocol regimens in patients with relapsed relapsed again after the second HSCT. One patient had leukemia [1]. We want to add our experience with clofarabine previously received allogeneic HSCT due to Ph (+) ALL; in children with multi-relapsed acute lymphoblastic and he relapsed after the HSCT and was unresponsive to the therapy protocol with clofarabine. Although clofarabine was myeloblastic leukemia. We analyzed the data of 12 children effective to induce remission, overall survival was poor in (1-13 years old) treated with the CLOVE protocol [clofarabine our study. The 3-month and 12-month overall survival rates (4 mg/m2), cyclophosphamide (440 mg/m2), and etoposide (100 mg/m2) for 5 days] [2,3,4] for relapsed or refractory acute leukemia between 2009 and 2013.
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]